Emergency Medicine Reports - June 25, 2006

Target Audience:

This continuing medical education activity is intended for emergency physicians.


AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is approved by the American College of Emergency Physicians for 2.25 ACEP Category 1 credits.

This activity has been reviewed and is acceptable for up to 1.5 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins 01/01/06. Term of approval is for one year from this date. Credit may be claimed for 1 year from the date of this issue.

Credit Designation:

AHC Media designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


CME Question Reviewer
Roger Farel, MD
Newport Beach, CA

Larissa I. Velez, MD
Department of Emergency Medicine
University of Texas Southwestern

Javier Caldera, MD
Department of Emergency Medicine
University of Texas Southwestern

Sing-Yi Feng, MD
Department of Emergency Medicine
University of Texas Southwestern

Ellen O'Connell, MD
Department of Emergency Medicine
University of Texas Southwestern

Peer Reviewers
Frank LoVecchio, DO, MPH, FACEP
Research Director
Maricopa Medical Center;
Medical Director
Banner Poison Center
Phoenix, AZ

Barry H. Rumack, MD
Director Emeritus
Rocky Mountain Poison and Drug Center
Clinical Professor of Pediatrics
University of Colorado Health Sciences Center

Sandra M. Schneider, MD
Professor and Chair
Department of Emergency Medicine
University of Rochester
School of Medicine Rochester
New York

J. Stephan Stapczynski, MD
Emergency Medicine Department
Maricopa Medical Center
Phoenix, Arizona

Gideon Bosker, MD
Special Clinical Projects
Medical Education Resources
Assistant Clinical Professor
Section of Emergency Services
Yale University School of Medicine
New Haven, Connecticut


  • Adverse Drug Reactions for the Emergency Physician: Part II


  • quickly recognize or increase index of suspicion for specific conditions
  • understand the epidemiology, etiology, pathophysiology, and clinical features of the entity discussed
  • apply state-of-the-art diagnostic and therapeutic techniques (including the implications of pharmaceutical therapy discussed) to patients with the particular medical problems discussed
  • understand the differential diagnosis of the entity discussed
  • understand both likely and rare complications that may occur

Financial Disclosure:

To reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, we disclose that Roger Farel, MD (cme question reviewer) owns stock in Johnson & Johnson. Larissa I. Velez, MD (co-author), Javier Caldera, MD (co-author), Sing-Yi Feng, MD (co-author), Ellen O'Connell, MD (co-author), Frank LoVecchio, DO, MPH, FACEP (peer reviewer), and Barry H. Rumack, MD (peer reviewer), and Sandra M. Schneider, MD (editor) report no relationships with companies related to the field of study covered by this CME activity. J. Stephan Stapczynski, MD (editor) reports that he served as a consultant on the drugs linezolid and dalbavancin. Gideon Bosker, MD (editor in chief) has been compensated for speaking engagements and/or editorial services related to production of peer-reviewed Clinical Consensus Reports under the auspices of unrestricted educational grants for Pfizer, Sanofi-Aventis, Bristol-Myers Squibb, Roche Pharmaceuticals, Bayer, Novartis, Forest Pharmaceuticals, and Schering Plough Corporation. Dr. Bosker also acknowledges that he has received royalties, commissions, and other compensation relating to the sale of textbooks, reprints of articles, and/or other electronic or print materials to the following pharmaceutical companies: Pfizer, Sanofi-Aventis, Bayer, Roche, Forest Laboratories, and Novartis. He is a minor stockholder in Pfizer. Any other stock ownership which he may have in other pharmaceutical companies is managed in blinded fashion by an independent consultant without Dr. Bosker's input or consultation.

Copyright 2006 AHC Media. All rights reserved.